Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-[(4Ar,7Ar)-Octahydro-6H-Pyrrolo[3,4-B]Pyridin-6-Yl]-4-Oxo-, Hydrochloride (1:1), Rel- is a highly specialized fluoroquinolone derivative serving as a critical synthetic intermediate in the development of next-generation antibacterial pharmaceuticals. It delivers exceptional structural precision required for high-yield, regioselective coupling in active pharmaceutical ingredient (API) synthesis — directly supporting accelerated process development and stringent impurity control. This compound is essential for research laboratories, contract development and manufacturing organizations (CDMOs), and API manufacturers focused on novel anti-infective agents targeting multidrug-resistant pathogens.

Application

• Synthetic intermediate for advanced fluoroquinolone antibiotics with enhanced Gram-positive and anaerobic activity
• Key building block in the preparation of clinical-stage antibacterial candidates targeting resistant Staphylococcus aureus and Clostridioides difficile
• Used in structure–activity relationship (SAR) studies to optimize C-7 pyrrolopyridine side-chain pharmacokinetics
• Critical reagent for solid-phase and solution-phase API route scouting under GMP-aligned development conditions
• Reference standard for analytical method development (HPLC, LC-MS) in quality control laboratories
• Material for stability-indicating assay validation per ICH Q2(R2) guidelines

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-[(4Ar,7Ar)-Octahydro-6H-Pyrrolo[3,4-B]Pyridin-6-Yl]-4-Oxo-, Hydrochloride (1:1), Rel-
CAS No.	1346603-25-5
Molecular Formula	C22H24FN3O4·HCl
Molecular Weight	465.91 g/mol
Synonyms	Garenoxacin hydrochloride (rel-); (±)-Garenoxacin hydrochloride; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride; Rel-Garenoxacin HCl; CP-115,953 hydrochloride; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, rel-; NSC 733070; UNII-92Z6QK8D4L
EINECS	Not listed

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards. Certificates of Analysis (COA) are available upon request. All batches conform to strict specifications for identity, assay, residual solvents, heavy metals, and related substances — fully aligned with ICH Q3A(R2)/Q3B(R2) guidelines and suitable for use in preclinical and clinical API synthesis. Testing includes HPLC purity determination, IR spectroscopic confirmation, chiral purity assessment, and residual chloride quantification.

Storage

Preserve in a tightly closed container, protected from light. Store at 15–25°C in a dry, well-ventilated area. Due to its hygroscopic nature, minimize exposure to ambient humidity and avoid repeated opening of the container.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Assay (HPLC)	98.5% – 101.0%
Related Substances (HPLC)	≤ 1.5% total impurities; individual impurity ≤ 0.5%
Residual Solvents (GC)	Meets ICH Q3C limits (e.g., acetone ≤ 5000 ppm, methanol ≤ 3000 ppm)
Water (KF)	≤ 1.0%
Heavy Metals	≤ 10 ppm
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.